Gil Naor, founder and CEO, MitrAssist Medical Ltd., a company that is the developer of minimally invasive products for treating heart disease, announces that the company has received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses.
Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open-heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of function and mechanism, known to be crucial for long-term patient outcome. MitrAssist's mitral valve prosthesis is delivered with a minimally invasive procedure via a small-diameter catheter, keeping the existing valve intact. With its unique design focused on natural mitral valve anatomy, the MitrAssist mitral valve prosthesis will enable faster transition to minimally invasive procedures for mitral repair.
"This is yet another small step for us moving forward towards developing a viable and effective solution to Mitral Valve Insufficiency, following our successful completion of the chronic animal study POC," Naor states
Latest from Today's Medical Developments
- Syringe-less injector system for diagnostic imaging obtains fourth FDA clearance
- Hohenstein Medical debuts enhanced medical device testing capabilities
- Arterex unveils unified brand identity
- Dymax demonstrates light-curing material solutions for medical devices
- Able Medical Devices showcases latest sternal closure solutions
- TMTS 2026 explores AI-powered sustainable manufacturing and more
- QT9 QMS platform streamlines quality management, compliance for medical device manufacturers
- Spineology releases patient-specific expandable spinal implant
